Scope and Claim Construction of U.S. Patent 6,488,960 (Controlled-Release Prednisone/Methylprednisolone/Prednisolone for 2–8 Hour Release)
U.S. Patent 6,488,960 centers on a specific controlled-release corticosteroid formulation and tied rheumatoid arthritis treatment method. Claim scope is anchored by (i) drug identity limited to prednisone, methylprednisolone, and prednisolone; (ii) dose range capped at 2 mg; and (iii) a defined dissolution/release performance: at least 90% by weight released between 2 and 8 hours post-administration. The estate’s practical value is in blocking competitors attempting to market or develop alternative corticosteroid controlled-release dosage forms that fall within those numeric boundaries, particularly for RA.
What claims define the scope of U.S. Patent 6,488,960 (controlled-release corticosteroid with 2–8 hour release)?
Claim 1: Composition with release-performance constraint
Core claim element set
- Dosage strength: 0.25 mg to 2 mg corticosteroid per controlled-release formulation.
- Corticosteroid identity (closed Markush group): selected from prednisone, methylprednisolone, prednisolone.
- Release performance: formulation is “adapted to release at least 90% by weight” of the corticosteroid from 2 hours to 8 hours after administration.
Scope implications
- The corticosteroid identity is narrow because it is limited to a closed group of three steroids.
- The dose range limits coverage by strength. Products outside 0.25–2 mg are outside literal claim 1 even if they use the same release profile.
- The performance definition is numeric and time-windowed. If the competitor demonstrates that release is either below 90% in that 2–8 hour window or that the release timing is materially different (for example, a different window or a significantly delayed/accelerated profile), literal infringement is less likely.
Claims 2–4: Narrowing limits
- Claim 2: same structure as claim 1 but dose constrained to 0.5–2 mg.
- Claim 3: dose constrained to 1–1.25 mg.
- Claim 4: corticosteroid specifically prednisolone.
Scope implications
- These are narrower dependent claims layered on top of claim 1.
- They are valuable for enforcing against products marketed in specific strengths (especially 1–1.25 mg prednisolone controlled-release).
What does Claim 5 cover: method-of-treatment for rheumatoid arthritis using the same formulation?
Claim 5: RA treatment method tied to the controlled-release formulation
Core method elements
- Therapeutic indication: treatment of rheumatoid arthritis.
- Administration: administering an effective amount of the controlled-release formulation.
- Formulation constraints (incorporated by reference to claim 1):
- corticosteroid in 0.25–2 mg
- steroid identity restricted to prednisone/methylprednisolone/prednisolone
- performance: at least 90% by weight released from 2 to 8 hours
Scope implications
- The claim is not a “generic RA treatment with steroids.” It is a method claim that requires the same controlled-release formulation performance parameters.
- A competitor could potentially avoid method infringement by changing the release kinetics, dose strength, or the steroid identity (or by using a different controlled-release system that fails the “adapted to release at least 90%…2 to 8 hours” criterion).
Claims 6–8: method limits by strength and steroid identity
- Claim 6: 0.5–2 mg dosing range.
- Claim 7: 1–1.25 mg dosing range.
- Claim 8: corticosteroid is prednisolone.
How strong is the numeric release-performance limitation for infringement and design-around?
Release-performance claim language: “adapted to release at least 90% by weight … 2 hours to 8 hours”
This creates a measurable functional limitation. For patent enforcement, the key question becomes whether the accused product’s release profile, under the relevant test conditions used to prove the formulation’s adaptation, meets:
- Percent: ≥90% by weight
- Timing window: release occurs between 2 and 8 hours after administration
Potential design-around vectors
Without addressing specific formulation specifics, the numerical boundary suggests these competitive levers:
- Dose strength: move outside 0.25–2 mg, or more tightly, outside 0.5–2 mg or 1–1.25 mg if aiming to avoid the dependent claims.
- Release window: shift the release such that ≥90% by weight is not released within 2–8 hours (for example, faster release mostly before 2 hours or slower release where less than 90% is reached by 8 hours).
- Steroid identity: swapping to a corticosteroid not in the closed group avoids literal coverage (e.g., drugs other than prednisone/methylprednisolone/prednisolone).
Claim construction risk for competitors
“Adapted to release” can be argued to require functional capability rather than a guaranteed release outcome in every scenario. Still, the patent’s numeric thresholds are likely to drive claim construction toward measurable dissolution/release evidence.
What is the likely claim breadth across dosage forms and controlled-release technologies?
Open-ended formulation structure
The claims do not recite excipients, polymer types, coatings, matrix versus reservoir design, or manufacturing steps. The only formulation content restrictions are:
- steroid identity
- dose quantity
- the release performance
Resulting breadth
- The patent likely covers a range of controlled-release dosage forms (tablet, capsule, coated pellets, etc.) as long as they meet the release criterion and dosage/steroid identity constraints.
- Competitors cannot assume a different controlled-release technology avoids the patent if release performance still matches the numeric requirement.
How do claims 1–8 map to infringement theories (literal infringement vs. equivalents)?
Literal infringement
A product likely infringes if it satisfies all limitations:
- steroid is one of the three named corticosteroids
- dose amount is in the required range
- in vivo or in vitro release profile meets ≥90% by weight between 2 and 8 hours
Literal infringement is strongest where product labels, strength tables, and dissolution data reflect the same numeric window.
Doctrine of equivalents
If a competitor misses the window by a small margin (for example, slightly less than 90% in 2–8 hours or the majority released just outside the time window), equivalents arguments may arise. The numeric precision typically increases the factual sensitivity of these disputes.
What patent landscape questions matter for U.S. Patent 6,488,960 (estate scope, expiry timing, and surrounding blocking patents)?
Key landscape buckets
For a controlled-release corticosteroid patent family, the competitive reality is usually shaped by nearby patents that cover one or more of:
- controlled-release excipient systems (matrix/reservoir/polymer/coat)
- specific steroid particle properties (if relevant)
- method-of-treatment or dosing regimens for RA
- additional strengths and specific steroids (prednisolone-specific claims like claim 4 and 8)
How to read this patent inside a portfolio
U.S. 6,488,960 is a “performance-bound controlled-release claim.” It typically functions as:
- a claim anchor on release kinetics
- a strength and steroid-identity fence
- an RA-use enforcement lever through claim 5 and its dependents
In licensing or litigation, this is usually paired against:
- patents with broader steroid families but different release criteria
- patents with matching steroid and release but different strength ranges
- patents focusing on manufacturing method (which may not be directly asserted through composition claims)
- regulatory and labeling exclusivity that can extend practical market control beyond patent expiry
Evidence likely to matter
- formulation dissolution/release studies
- in vitro testing protocols and acceptance criteria
- product development records showing “adapted” design targets
What is the commercial risk profile: where do generic or alternative controlled-release products hit the claim boundaries?
Highest infringement risk areas
- Same steroid identity (prednisone, methylprednisolone, or prednisolone).
- Strength within 0.25–2 mg, especially 0.5–2 mg or 1–1.25 mg.
- Release profiles meeting ≥90% by weight between 2 and 8 hours.
Lower risk areas (clean design-out)
- strength outside the claimed ranges
- different steroid identity not included in the closed group
- controlled-release profiles that fail the 2–8 hour, 90% threshold
How does Claim 5 affect “skinny labeling” or non-RA use strategies?
Indication limitation
Claim 5 requires “treatment of rheumatoid arthritis.” If a competitor markets a controlled-release corticosteroid without positioning it for RA (or markets for a different indication), method claim risk changes. Still, enforcement can depend on:
- promotional claims
- prescribing information
- off-label use evidence (varies by jurisdiction and enforcement posture)
From a portfolio perspective, claim 5 is an RA-specific lever, while claims 1–4 are composition-level barriers independent of indication.
What patent interpretation issues can materially change scope?
“Release at least 90% by weight … 2 hours to 8 hours”
This phrasing raises claim interpretation questions commonly litigated:
- Whether the 2–8 hour window is based on cumulative release by the end of 8 hours or incremental release within the window
- Whether “adapted to release” requires a particular test method or prescribes only functional capability
- Whether “by weight” is tied to the same reference basis across products
The numeric thresholds make these issues outcome-determinative.
Dose unit meaning
Dose range is stated as amount of corticosteroid in mg within the formulation. In litigation, disputes can arise over:
- how strength is measured for combination products (not indicated in claim text)
- whether “effective amount” in claim 5 changes the relevance of the mg limitations
Key structured claim scope table
| Claim |
Claim type |
Corticosteroid(s) covered |
Strength range (mg) |
Release constraint |
Disease/Use |
| 1 |
Composition |
prednisone, methylprednisolone, prednisolone |
0.25–2 |
≥90% by weight released 2–8 hours |
Not limited |
| 2 |
Composition (dependent) |
same as claim 1 |
0.5–2 |
same as claim 1 |
Not limited |
| 3 |
Composition (dependent) |
same as claim 1 |
1–1.25 |
same as claim 1 |
Not limited |
| 4 |
Composition (dependent) |
prednisolone only |
0.25–2 |
same as claim 1 |
Not limited |
| 5 |
Method |
same as claim 1 |
0.25–2 |
same as claim 1 |
rheumatoid arthritis |
| 6 |
Method (dependent) |
same as claim 5 |
0.5–2 |
same as claim 5 |
rheumatoid arthritis |
| 7 |
Method (dependent) |
same as claim 5 |
1–1.25 |
same as claim 5 |
rheumatoid arthritis |
| 8 |
Method (dependent) |
prednisolone only |
0.25–2 |
same as claim 5 |
rheumatoid arthritis |
Key Takeaways
- U.S. 6,488,960 is a controlled-release corticosteroid patent defined by three hard fences: (1) steroid identity limited to prednisone, methylprednisolone, prednisolone; (2) dose range limited to 0.25–2 mg (with dependent ranges at 0.5–2 mg and 1–1.25 mg); and (3) release performance requiring ≥90% by weight between 2 and 8 hours.
- Claims 1–4 create composition-level barriers across indications; claim 5 creates a rheumatoid-arthritis-specific method-of-use barrier using the same controlled-release formulation constraints.
- The absence of excipient or manufacturing limitations broadens coverage across controlled-release technologies, as long as release kinetics and strengths hit the numeric parameters.
- Competitor design-around is most plausible by moving out of the strength window, shifting the release-time profile such that the ≥90% 2–8 hour threshold is not met, or using corticosteroids outside the closed Markush group.
FAQs
- What if my controlled-release product releases ≥90% by 9 hours instead of by 8 hours?
- Does the patent cover tablets and capsules, or only one dosage form?
- How do I assess whether a product meets “adapted to release at least 90% by weight” under the claim?
- If a product is approved for a non-RA indication, does claim 5 still matter?
- Which claim is most useful against a competitor marketing prednisolone 1–1.25 mg controlled-release: claim 3 or claim 7?
References
No sources were provided in the prompt for U.S. Patent 6,488,960’s specification, prosecution history, issuance data, or later citations.
